The sequencing system will allow healthcare to move closer to preventive precision medicine which will benefit everyone
Redcliffe Labs, a unit of Redcliffe Lifetech in the US, has announced the addition of ‘NovaSeq 6000’ sequencing system to their diagnostic technology portfolio at its Noida National Reference Lab.
Ease of access to NovaSeq 6000 sequencing system will prove to be very useful, as currently there’s no mass-level testing protocol rolled out by the states for genetic diseases. Following the successful adoption of NovaSeq 6000 technology, high throughput speed and flexibility will be available to conduct research or tests that need the processing of massive amounts of data more efficiently and cost-effectively.
Dheeraj Jain, Founder, Redcliffe Labs said, “The addition of the world’s most advanced genome sequencing system for newborn and rare diseases will equip us to offer the most comprehensive suite of genetic testing services that find significant applications in rare and novel genetic variants. Doctors from specialities such as gynaecologists, obstetricians and paediatricians who we are serving with our routine portfolio, requested us to build a specialised portfolio given our quality and reach are so wide and no private lab in the Northern region of India has housed such a powerful sequencer. Hence, we decided to fill the gap which will facilitate us in offering high-throughput sequencing across a wide range of applications. It also enables researchers to investigate genetic relationships between health and disease on a massive scale by allowing them to sequence more samples in greater depth to find rare and novel genetic variations.”
Moreover, the sophisticated sequencing system will allow healthcare to move closer to preventive precision medicine which will benefit everyone.
Praveen Gupta, MD, Premas Life Sciences said, “Our company is happy to work with Redcliffe to support their diagnostic efforts with the addition of NovaSeq 6000, a world-class next-generation sequencing technology. This is indeed a huge step forward for Redcliffe and the medical community. It will greatly increase sequencing throughput and allow for precise and rapid whole-exome and whole-genome sequencing results. This will result in faster diagnosis and treatment for patients.”
